[Yung Shin] Announcement of the Approval of Non-Compete Restriction Removal for Directors at the 2026 Annual General Meeting
Yung Shin Pharmaceutical announced that the 2026 AGM approved the removal of non-compete restrictions for three directors. Director Li Fang-chuan will hold a concurrent position at De-Zhen Pharmaceutical (Jiangsu) Co., Ltd., with no material impact on the company's finances.
📋 Article Processing Timeline
- 📰 Published: May 27, 2026 at 09:00
- 🔍 Collected: May 28, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 31, 2026 at 19:09 (83h 9m after Collected)
1. Date of Shareholders' Meeting Resolution: 2026/05/27
2. Names and titles of directors permitted to engage in competitive activities:
(1) Director: Li Ling-jin
(2) Director: Representative of Bio-Tech Holdings Co., Ltd.: Li Fang-yu
(3) Director: Representative of Yung-Chuan Investment Co., Ltd.: Li Fang-chuan
3. Items permitted: Investing in or managing companies with the same or similar business scope as the company, and serving as a director or manager.
4. Duration: During the term of office as a director of the company.
5. Resolution details (pursuant to Article 209 of the Company Act): Passed as proposed after a vote by shareholders representing at least two-thirds of the total issued shares.
6. Directors involved in competitive activities in mainland China:
Director: Representative of Yung-Chuan Investment Co., Ltd.: Li Fang-chuan
7. Name and position in the mainland Chinese entity: Director of De-Zhen Pharmaceutical (Jiangsu) Co., Ltd.
8. Address of the mainland Chinese entity: No. 191, Jinyang West Road, Lujia Town, Kunshan City, Jiangsu Province.
9. Business scope of the mainland Chinese entity: Pharmaceutical wholesale, pharmaceutical retail, and food sales.
10. Impact on the company's financial and business operations: No material impact.
11. Investment amount and shareholding ratio in the mainland Chinese entity: None.
12. Other matters: None.
2. Names and titles of directors permitted to engage in competitive activities:
(1) Director: Li Ling-jin
(2) Director: Representative of Bio-Tech Holdings Co., Ltd.: Li Fang-yu
(3) Director: Representative of Yung-Chuan Investment Co., Ltd.: Li Fang-chuan
3. Items permitted: Investing in or managing companies with the same or similar business scope as the company, and serving as a director or manager.
4. Duration: During the term of office as a director of the company.
5. Resolution details (pursuant to Article 209 of the Company Act): Passed as proposed after a vote by shareholders representing at least two-thirds of the total issued shares.
6. Directors involved in competitive activities in mainland China:
Director: Representative of Yung-Chuan Investment Co., Ltd.: Li Fang-chuan
7. Name and position in the mainland Chinese entity: Director of De-Zhen Pharmaceutical (Jiangsu) Co., Ltd.
8. Address of the mainland Chinese entity: No. 191, Jinyang West Road, Lujia Town, Kunshan City, Jiangsu Province.
9. Business scope of the mainland Chinese entity: Pharmaceutical wholesale, pharmaceutical retail, and food sales.
10. Impact on the company's financial and business operations: No material impact.
11. Investment amount and shareholding ratio in the mainland Chinese entity: None.
12. Other matters: None.
FAQ
What is Article 209 of the Taiwan Company Act?
It requires directors to obtain shareholder approval before engaging in competitive business activities that overlap with the company's scope.